CA
NZ
UK
AU
IND
US
• Formal Deficiency Notice Received June 30: Nasdaq's Listing Qualifications Department notified Mdxhealth on June 30, 2026, that it failed to satisfy minimum bid price criteria.
• Full Biocompatibility Pass: Polyrizon (NASDAQ: PLRZ) confirmed its NASARIX Allergy Blocker passed all ISO 10993 and FDA biocompatibility tests.
• USPTO Notice of Allowance: Galmed Pharmaceuticals (NASDAQ: GLMD) received a Notice of Allowance for a patent covering methods to treat and inhibit fibrosis.
• Four AI-Identified Molecules Tested: NorthStrive's AI-driven collaboration with Yuva Biosciences identified four small molecules that improved ANT1 expression in primary skeletal muscle cells.
• FDA Clearance Secured: Tenon Medical (NASDAQ: TNON) received 510(k) clearance for its Catamaran SI Joint Fusion System from the U.S. Food and Drug Administration.
• 37% Share Price Decline on Dilution: Shares fell 37% to $3.22 following the registered direct offering announcement, reflecting the significant dilutive impact on existing shareholders.
• $15 Million Raised: Elicio Therapeutics (NASDAQ: ELTX) closed a registered direct offering of 4.38 million shares, raising approximately $15 million gross.
• 770,000 Shares Purchased at $0.1956: The company acquired 770,000 additional shares through open market purchases at an average cost of approximately $0.1956 per share.
• Late-Breaking Selection: Tenax Therapeutics (NASDAQ: TENX) will present Phase 3 LEVEL trial data at a Late-Breaking Clinical Science session at ESC Congress 2026 in Munich.
• Late-Breaking ESC 2026 Session Selected: Phase 3 LEVEL trial data for TNX-103 was selected for a Late-Breaking Clinical Science session at the ESC Congress 2026 in Munich on August 29, 2026.
Please wait processing your request...